Tracer library / [177Lu]Lu-PEG-(DOTA)1
[177Lu]Lu-PEG-(DOTA)1
Also written as [Lu-177]PEG-(DOTA)1
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- PEGylated DOTA-chelated nanocarrier (non-targeted control, lacking PSMA-binding ligand)
- Target / mechanism
- —
- Clinical application
- Prostate cancer PMID 38700450
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | 70.9-76.6% | — | PEG-(DOTA)1 | 38700450 2024 Adv Healthc Mater StarPEG nanocarrier in water was added to a solution of 10 mM NH4OAc containing 10 vol% of ascorbic acid (20 mg/mL) and 177LuCl4 in a ratio of 0.37 MBq/μg of nanocarriers were mixed to it. - the isolated yield and molar activities for [177Lu]PEG-(DOTA)1 ranged from 70.9-76.6% and 10.8-11.5 MBq/nmol, respectively |
Need this precursor?We can point you to suppliers for [177Lu]Lu-PEG-(DOTA)1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38700450. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 38700450: 'PEG-(DOTA)1 (Yield 93%, 90 mg)'. Stage set/updated at stage 39 from PMID 38700450: 'The radiolabeled nanodrugs, [177Lu]PEG-(DOTA)1 and [177Lu]PEG-(DOTA)1(ACUPA)3, are evaluated in vitro and in vivo using PSMA+ PC3-Pip and/or PSMA- PC3-Flu cell lines, subcutaneous xenografts and disseminated metastatic models.'.